252 related articles for article (PubMed ID: 23624841)
1. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
Jain AK; Raina K; Agarwal R
Cell Cycle; 2013 May; 12(10):1598-604. PubMed ID: 23624841
[TBL] [Abstract][Full Text] [Related]
2. P21 and P27 promote tumorigenesis and progression via cell cycle acceleration in seminal vesicles of TRAMP mice.
Li T; Wang F; Dang Y; Dong J; Zhang Y; Zhang C; Liu P; Gao Y; Wang X; Yang S; Lu S
Int J Biol Sci; 2019; 15(10):2198-2210. PubMed ID: 31592235
[TBL] [Abstract][Full Text] [Related]
3. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
4. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.
Romics I; Bánfi G; Székely E; Krenács T; Szende B
Pathol Oncol Res; 2008 Sep; 14(3):307-11. PubMed ID: 18415709
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
[TBL] [Abstract][Full Text] [Related]
6. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
7. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
9. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
Peek EM; Song W; Zhang H; Huang J; Chin AI
Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
[TBL] [Abstract][Full Text] [Related]
10. Iodine uptake and prostate cancer in the TRAMP mouse model.
Olvera-Caltzontzin P; Delgado G; Aceves C; Anguiano B
Mol Med; 2013 Nov; 19(1):409-16. PubMed ID: 24306422
[TBL] [Abstract][Full Text] [Related]
11. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
Tepaamorndech S; Huang L; Kirschke CP
Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
[TBL] [Abstract][Full Text] [Related]
12. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
Escara-Wilke J; Keller JM; Ignatoski KM; Dai J; Shelley G; Mizokami A; Zhang J; Yeung ML; Yeung KC; Keller ET
Prostate; 2015 Feb; 75(3):292-302. PubMed ID: 25327941
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.
Kalin TV; Wang IC; Ackerson TJ; Major ML; Detrisac CJ; Kalinichenko VV; Lyubimov A; Costa RH
Cancer Res; 2006 Feb; 66(3):1712-20. PubMed ID: 16452231
[TBL] [Abstract][Full Text] [Related]
14. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
[TBL] [Abstract][Full Text] [Related]
15. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice.
Kelavkar UP; Glasgow W; Olson SJ; Foster BA; Shappell SB
Neoplasia; 2004; 6(6):821-30. PubMed ID: 15720809
[TBL] [Abstract][Full Text] [Related]
17. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
18. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.
Li X; Yokoyama NN; Zhang S; Ding L; Liu HM; Lilly MB; Mercola D; Zi X
Oncotarget; 2015 Dec; 6(39):41809-24. PubMed ID: 26497688
[TBL] [Abstract][Full Text] [Related]
19. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.
Teichert F; Verschoyle RD; Greaves P; Edwards RE; Teahan O; Jones DJ; Wilson ID; Farmer PB; Steward WP; Gant TW; Gescher AJ; Keun HC
Prostate; 2008 Jul; 68(10):1035-47. PubMed ID: 18459103
[TBL] [Abstract][Full Text] [Related]
20. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]